Back to results
US 8,206,706 B2Granted
Method for enhancing or inhibiting insulin-like growth factor-I
AssigneeThe University of North Carolina at Chapel Hill
InventorsDavid R. Clemmons, Laura A. Maile
Life of this patent
Estimating the term…
Abstract
The present invention provides αVβ3 integrin cysteine loop domain agonists and antagonists (including peptide agonists and antagonists and analogs thereof), along with methods of using the same.
Claims3
A method of inhibiting IGF-1 actions in a subject in need thereof, comprising administering to said subject an αVβ3 integrin cysteine loop domain antagonist in an amount effective to inhibit IGF-1 actions in said subject,
- wherein said antagonist is an antibody that:
- (a) specifically binds to the cysteine loop domain at amino acids 177 to 184 of a human β3 integrin, wherein said amino acids consist of SEQ ID NO:82;
- (b) does not specifically bind to the RGD binding site of a human β3 integrin;
- and (c) specifically binds to the cysteine loop domain at amino acids 177 to 184 of a pig β3 integrin, wherein said amino acids consist of SEQ ID NO:
- 82 and wherein said subject has atherosclerosis, and said antagonist is administered in an amount effective to treat said atherosclerosis.
2 more elements
Dependencies are inferred from the claim text.